{
  "content": "Diagnosis:\nMetastatic sigmoid colon cancer (serrated adenocarcinoma)\nDuke's C2, MSI-low, BRAF non-V600E mutant\n\nPrevious treatment:\nAnterior resection March 2023\nAdjuvant CAPOX completed September 2023\nPulmonary metastases identified December 2023\nFOLFIRI/Bevacizumab commenced January 2024\n\nCurrent situation:\nCycle 4 FOLFIRI/Bevacizumab review\n\nDisease status:\nCT chest 15 April 2024 shows progression of pulmonary metastases\nNew 2cm right lower lobe nodule\nExisting nodules increased by >30%\nCEA risen from 45 to 89\n\nCurrent symptoms:\nIncreasing breathlessness on exertion\nNew dry cough\nWeight loss 3kg over 6 weeks\nPerformance status deteriorated to ECOG 2\n\nPrevious medical history:\nType 2 diabetes\nHypertension\n\nCurrent medications:\nFOLFIRI/Bevacizumab regime\nMetformin 1g BD\nRamipril 5mg OD\n\nPlan:\nDiscontinue FOLFIRI/Bevacizumab due to disease progression\nCommence Trifluridine/Tipiracil (Lonsurf) as third-line therapy\nDose calculated at 35mg/m2 BD days 1-5 and 8-12 of 28-day cycle\nReview in 2 weeks with blood tests\nRepeat CT after cycle 2\nReferral made to palliative care team for symptom management",
  "output": {
    "primary_cancer": {
      "site": "sigmoid colon",
      "year": 2023,
      "month": 3,
      "metastases": "pulmonary metastases",
      "other_stage": "Duke's C2",
      "histopathology_status": "serrated adenocarcinoma",
      "biomarker_status": "MSI-low, BRAF non-V600E mutant",
      "cancer_timeline": [
        {
          "type": "treatment_surgery",
          "value": "Anterior resection",
          "year": 2023,
          "month": 3
        },
        {
          "type": "treatment_systemic_start",
          "value": "Commenced adjuvant CAPOX",
          "year": 2023,
          "month": 3
        },
        {
          "type": "treatment_systemic_change",
          "value": "Completed adjuvant CAPOX",
          "year": 2023,
          "month": 9
        },
        {
          "type": "anatomical_finding",
          "value": "Pulmonary metastases identified",
          "year": 2023,
          "month": 12
        },
        {
          "type": "treatment_systemic_start",
          "value": "Started FOLFIRI/Bevacizumab",
          "year": 2024,
          "month": 1
        },
        {
          "type": "anatomical_finding",
          "value": "CT shows progression of pulmonary metastases with new 2cm right lower lobe nodule",
          "year": 2024,
          "month": 4
        },
        {
          "type": "laboratory_finding",
          "value": "CEA risen from 45 to 89",
          "year": 2024,
          "month": 4
        }
      ]
    },
    "patient_facts": [
      {
        "type": "performance_status",
        "value": "ECOG 2"
      },
      {
        "type": "comorbidity",
        "value": "Type 2 diabetes"
      },
      {
        "type": "comorbidity",
        "value": "Hypertension"
      },
      {
        "type": "current_symptom",
        "value": "Increasing breathlessness on exertion"
      },
      {
        "type": "current_symptom",
        "value": "New dry cough"
      },
      {
        "type": "quality_of_life_finding",
        "value": "Weight loss 3kg over 6 weeks"
      }
    ],
    "status_updates": [
      {
        "type": "clinical_summary",
        "value": "Metastatic sigmoid cancer progressing on second-line therapy with deteriorating symptoms and performance status"
      },
      {
        "type": "latest_treatment_response",
        "value": "Disease progression with new and enlarging pulmonary metastases and rising CEA"
      },
      {
        "type": "update_to_treatment",
        "value": "Discontinuing FOLFIRI/Bevacizumab and commencing Trifluridine/Tipiracil"
      },
      {
        "type": "updated_patient_functional_status",
        "value": "Performance status deteriorated to ECOG 2 with increasing breathlessness"
      },
      {
        "type": "planned_investigation",
        "value": "Repeat CT after cycle 2 of Trifluridine/Tipiracil"
      },
      {
        "type": "follow_up_referral",
        "value": "Review in 2 weeks with blood tests and referral to palliative care team"
      }
    ]
  }
}